Page 40 - Sohini Das

Schedule M of Drugs and Cosmetics Act to be made must for all pharma units

Govt wants units to move towards GMP through self regulation

Wockhardt charting a recovery riding on a promising new antibiotic

While global trials are on, doctors have started using one of company's antibiotics against superbugs to save lives

Robust Jaguar Land Rover sales in June quarter power up Tata Motors

Wholesale, retail volumes up 30% and 29%, respectively

Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

Biocon Biologics eyes third of FY24 revenue from emerging markets

BBL, which launched Hulio, a biosimilars version of Abbvie's blockbuster drug Humira, in the US earlier this week, is planning to launch this drug in other countries in the near term

Bajaj-Triumph, Hero-Harley entry shifts premium bike race into top gear

Royal Enfield is also the undisputed leader in the 250cc-350cc segment, virtually owning the market at a whopping 94 per cent share

Biocon Biologics expands to over 70 countries, enters emerging markets

Completes integration of the acquired biosimilars business from Viatris

Biosimilar Humira likely to boost US revenues for Biocon Biologics

Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL's revenues from the current $1 billion to around $1.65 billion by FY25

Stelis sells Bengaluru facility to Biocon arm Syngene for Rs 702 cr

Both parties have entered into a binding term sheet to execute the deal whereby Syngene has acquired the unit 3 facility in Bengaluru for Rs 702 crore

'4IR': The booster pharma majors are taking to improve productivity

Large manufacturers are leveraging new-age technologies and advanced analytics to improve productivity and reduce deviations in production processes

Electric vehicle makers in talks with Centre on battery decoupling policy

The EV industry seems to be geared up for the change

USFDA observations in 2022 focus on ancillary infra, written procedures

45% observations in 2022 around unavailability of written procedures and facility maintenance, ancillary infrastructure

Lupin likely to demerge its active pharmaceutical ingredients business

As such the API business contributes around 7 percent to Lupin's overall turnover

We want to become the no. 1 diagnostics provider in the world: Mylab MD

'The Mylab ecosystem is capable of providing solutions'

WHO investigating more syrups, drug samples; list of alerts may expand

The WHO director-general issued a call to action in January to implore all member states to increase their surveillance and testing efforts because people are 'needlessly being put at risk'

Instead of cough syrup testing, need to go for root-cause analysis: Bhaskar

Pharmaceutical exports from India have come under the scanner after sporadic incidents of contaminated or substandard medicines

DRL enters trade generics, aims to be among top five players in market

Exploring strategic collaborations in the country, says pharma firm

Self-regulatory body for pharma industry on cards: Mansukh Mandaviya

Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants

Truck operators raise heat over govt's air-conditioned cabin proposal

But commercial vehicle OEMs welcome the move, saying demand for AC trucks is already going up

Will launch 10 vehicles this year: Mercedes-Benz India CEO Santosh Iyer

'And a majority will be in the top-end vehicle range', says Santosh Iyer